Quality of Life 1y and 2 y After VV-ECMO for COVID-19

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the quality of life and the outcome after veno-venous extracoporeal membrane oxygenation (ECMO) support fir severe acute respiratory syndrome (ARDS) in COVID-19 patients.

Detailed Description
-----------------
The investigators follow our COVID-19 patients supported by ECMO, we make phone calls or real-life visits to pthe patients to score the quality of life, by using the SF-36. The SF-36 measures eight scales: physical functioning, role physical, bodily pain, general health, vitality , social functioning , role emotional , and mental health. The participants are contacted 3 months, 6months, 1year and 2 years after the ECMO support started for evaluation of the SF-36.

Official Title
-----------------
Quality of Life 1y and 2 y After VV-ECMO for COVID-19, Measured by the 36-item Short Form Health Survey

Conditions
-----------------
COVID-19 Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation Complication, Quality of Life, Death

Intervention / Treatment
-----------------
* Device: VV-ECMO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with PCR-confirmed COVID-19 infection AND Acute Respiratory Distress Syndrome who require veno-venous ECMO therapy. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID-19 positive patients<br>Patients with a PCR-confirmed COVID-19 infection, with ARDS and supported by VV-ECMO | Device: VV-ECMO<br>* veno-venous extracorporeal membrane oxygenation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| in-hospital mortality |  | mortality during hospitalisation, up to two years | 
| Quality of life 1y after ECMO insertion | Result of SF-36 1 year after VV-ECMO insertion | 1 year | 
| Quality of life 2y after ECMO insertion | Result of SF-36 2 years after VV-ECMO insertion | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung complications requiring surgical treatment | Hemothorax or lung abcedation | From the start of VV-ECMO support until weaning of VV-ECMO, up to two years | 
| Duration of mechanical ventilation |  | 2 years | 
| LOS ICU | length of stay at the intensive care unit | from the day of intensive care unit admission until the day of transfer to the ward, up to two years | 
| LOS hospital | length of stay at the hospital | from the day of hospital admission until the day that the participant is transferred to home, up to two years | 
| death after hospital discharge | all-cause death | after discharge from the hospital upon 2 years after | 
| Incidence of acute kidney injury |  | from the day of hospital admission until the day that the participant is transferred to home, up to two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ECMO, COVID-19, quality of life